Biohaven Q3 2026 net loss narrows 25% to $129.28 million
BHVN•Biohaven’s third-quarter 2026 net loss narrowed 25% year over year to $129.28 million, while research and development expenses fell 28% to $101.85 million.
1. Quarterly results and pipeline
Biohaven’s third-quarter 2026 net loss narrowed 25% year over year to $129.28 million. Research and development expenses fell 28% to $101.85 million, primarily due to lower direct program and preclinical spending. A licensing agreement with SK Biopharmaceuticals provides $400 million in cash consideration, including $350 million payable at closing. The FDA paused new opakalim enrollment pending additional nonclinical safety studies; RISE 3 topline results remain expected in the second half of 2026. The FDA accepted the Vyglxia application resubmission for spinocerebellar ataxia, with a first-quarter 2027 user fee goal date.
